Introduction
============

Acute kidney injury (AKI) is frequent in critically ill patients admitted to intensive care units (ICUs) and is independently associated with increased morbidity and mortality \[[@B1]\]. For many years, serum creatinine (sCr) has been the principal marker of AKI even though it is widely acknowledged that sCr is not reliable during acute changes in kidney function and varies with gender, age, muscle mass, dietary intake, and hydration status. sCr does not reflect real-time decline in glomerular filtration rate (GFR), because creatinine has to accumulate as a result of a decrease in GFR before increased concentrations are detectable. A real-time marker of AKI may allow the institution of earlier, and therefore more effective, renoprotective therapies; one such marker is neutrophil gelatinase-associated lipocalin (NGAL).

NGAL, also known as lipocalin-2 (lcn2), is a 25-kDa protein and member of the lipocalin superfamily \[[@B2]\]. It was named after its expression in neutrophils and found to have bacteriostatic effects by interfering with bacterial siderophore-mediated iron uptake \[[@B3]\]. NGAL expression has been shown to increase in response to inflammation in epithelial cells regularly exposed to microorganisms \[[@B2]\] and in response to cellular oxidative stress \[[@B4]\]. Increases in plasma NGAL have been reported in a wide range of systemic diseases, including acute infections, pancreatitis, heart failure, and cancer \[[@B5]-[@B8]\], but in recent years the potential role of plasma and urinary NGAL as early markers of AKI has been studied. A study in mice showed marked urinary NGAL increase within 2 hours of renal injury, by far preceding conventional markers of AKI \[[@B9]\]. In children undergoing elective cardiac surgery, plasma and urinary NGAL measurements at 2 hours after surgery were highly predictive of the development of AKI within 72 hours; area under receiver operating characteristic curves (AuROCs) were 0.91 and 0.99, respectively \[[@B10]\]. Differences between plasma and urinary NGAL kinetics are likely because of local synthesis and excretion of NGAL in the distal tubules of the nephron, further supported by a calculated fractional NGAL excretion of more than 100% \[[@B11]\].

Patients admitted to the ICU have higher levels of comorbidity than other patient categories, possibly confounding the value of NGAL as a marker of AKI. This is supported by a study showing higher plasma and urinary NGAL levels in septic AKI versus non-septic AKI patients \[[@B12]\]. Also, the exact onset of a renal insult in intensive care patients is often less clear, and this further hampers the interpretation of elevated NGAL in these patients.

Therefore, the aim of this review was to systematically evaluate the predictive value of plasma and urinary NGAL measurement for AKI in ICU patients. Given the presumed confounding increase in measured NGAL during acute infections, we aimed to do a subgroup analysis in patients with sepsis.

Methods
=======

This systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@B13]\]. The following inclusion criteria were defined *a priori*: studies of adults in an ICU setting evaluating the value of urinary or plasma NGAL measurements (or both) as an early marker of AKI. Studies not performed primarily in an ICU setting (for example, surgery) and articles not in English were excluded.

Information sources and search strategy
---------------------------------------

We conducted an electronic search in MEDLINE through PUBMED database, EMBASE, and Cochrane Library in February 2012. The search was conducted with the following search string: (NGAL OR \'neutrophil gelatinase-associated lipocalin\' OR lipocalin-2 OR lcn2) AND (\'acute kidney injury\' OR AKI OR \'acute renal injury\' OR ARI OR \'acute renal failure\' OR ARF OR \'acute kidney failure\' OR AKF). Two authors (PH and MW) independently screened all articles for inclusion. Differences were discussed and resolved with a third party (AP). A supplemental search was conducted by screening citations of review articles and research papers to identify potential studies not included in the search string.

Study selection and data extraction
-----------------------------------

For studies that fulfilled inclusion criteria, two authors (PH and MW) independently extracted data by using a standardized extraction sheet (Supplemental Digital Content 1). When differences in opinion occurred, they were resolved by discussion involving a third party (AP). Data were extracted from each included trial on (a) study characteristics (including setting, inclusion and exclusion criteria, year of publication, and population size), (b) type of NGAL measurements (including plasma or urine or both, assay used, and timing and frequency of sampling), and (c) type of outcome measure (including AKI definition, observation period for AKI, use of renal replacement therapy (RRT), and mortality).

Assessment of methodological quality and risk of bias in individual studies
---------------------------------------------------------------------------

There are, to our knowledge, no specific guidelines on how to assess the methodological quality of individual studies of diagnostic markers. We used the following criteria to assess the risk of bias: (a) prospective study design and analysis, (b) a validated diagnostic scale defining AKI: Acute Kidney Injury Network (AKIN) or Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE), (c) clearly described selection criteria for study participants, (d) sufficient description of NGAL measurements permitting replication of the study, and (e) any potential conflict of interests described.

Both the RIFLE \[[@B14]\] criteria and the AKIN \[[@B15]\] criteria were accepted as validated diagnostic scales as they have shown comparable predictive values for mortality and ICU length of stay in a large cohort of ICU patients \[[@B16]\]. For studies using sCr criteria only, AKI definition was determined by modified RIFLE/AKIN and still accepted as valid. Studies fulfilling four or five criteria were classified as studies having low risk of bias, and if three criteria were fulfilled, the studies were classified as having medium risk of bias. Otherwise, they were classified as studies having high risk of bias.

Summary measures
----------------

AuROC was the primary measure for the value of NGAL to predict AKI, RRT, and mortality. Furthermore, the AuROC of AKI stratified for severity was extracted if reported. If NGAL thresholds were reported, sensitivity, specificity, and positive and negative predictive values were extracted. If the study conducted a sensitivity analysis to exclude patients with reduced kidney function on entry, AuROC and method were extracted.

Meta-analysis and subgroup analysis
-----------------------------------

We planned to conduct a meta-analysis of the predictive value of plasma and urinary NGAL for AKI and a subgroup analysis of patients with sepsis.

Results
=======

Study trial flow
----------------

The search string produced a total of 1,041 potentially relevant articles. No additional studies were found in the supplemental hand search, but one unpublished study was identified through personal contact. Figure [1](#F1){ref-type="fig"} shows the flowchart of study selection.

![**Flowchart of study selection**. ICU, intensive care unit; NGAL, neutrophil gelatinase-associated lipocalin.](cc11855-1){#F1}

Study characteristics
---------------------

We included 11 studies (Table [1](#T1){ref-type="table"}); for further study characteristics, see Supplemental Digital Content. The studies were published between 2009 and 2011; one study was only in abstract form, and one was unpublished at the time of analysis. Nine studies were in general ICU patients, one was in ICU patients with multiple trauma, and one study was in patients with septic shock. The 11 studies included a total number of 2,875 patients (range of 20 to 632).

###### 

Characteristics of included studies

  Study                             Year   Population size   Patients                            NGAL sample        Assay   AKI definition
  --------------------------------- ------ ----------------- ----------------------------------- ------------------ ------- ---------------------------
  de Geus *et al.*\[[@B21]\]        2011   632               General ICU                         Plasma and urine   FIA     RIFLE (sCr)
  Endre *et al.*\[[@B22],[@B23]\]   2011   528               General ICU                         Urine              ELISA   AKIN or RIFLE (sCr)
  Doi *et al.*\[[@B24]\]            2011   339               General ICU                         Urine              ELISA   RIFLE (sCr)
  Cruz *et al.*\[[@B25]\]           2010   301               General ICU                         Plasma             FIA     RIFLE (sCr + UO)
  Constantin *et al.*\[[@B26]\]     2010   88                General ICU                         Plasma             FIA     RIFLE (sCr)
  Mårtensson *et al.*\[[@B27]\]     2010   25                ICU patients with septic shock      Plasma and urine   RIA     RIFLE and AKIN (sCr + UO)
  Metzger *et al.*\[[@B28]\]        2010   20                General ICU                         Urine              ELISA   AKIN (sCr + UO)
  Siew *et al.*\[[@B29]\]           2009   451               General ICU                         Urine              ELISA   AKIN (sCr)
  Makris *et al.*\[[@B30]\]         2009   31                ICU patients with multiple trauma   Urine              ELISA   RIFLE (sCr + UO)
  Kokkoris *et al*.^a^\[[@B31]\]    2011   91                General ICU                         Plasma             FIA     RIFLE (sCr + UO)
  Linko *et al*.^b^                 2012   369               General ICU                         Plasma             FIA     \-

^a^Study published as abstract only; author contacted to obtain extracted data; ^b^study unpublished. AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ELISA, enzyme-linked immunosorbent assay; FIA, fluorescence immunoassay; RIA, radioimmunoassay; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney disease; sCr, serum creatinine; UO, urine output.

Five studies measured urinary NGAL only, four measured plasma NGAL only, and two studies measured both plasma and urine; that is a total of seven studies of urinary NGAL and six of plasma NGAL. All studies of plasma NGAL reported absolute concentration, whereas urinary NGAL studies varied: three reported NGAL in absolute concentration, and four reported NGAL normalized to urinary creatinine.

The included studies varied in kidney-specific exclusion criteria: some excluded patients with history of chronic kidney disease, and others excluded patients based on admission sCr. AKI definition varied among studies: four used either RIFLE or AKIN creatinine and urine output criteria, four used modified either RIFLE or AKIN with creatinine criteria only, one used both AKIN and RIFLE criteria, and one reported two AuROC values using modified AKIN and modified RIFLE criteria, respectively. In one study AKI was not reported, but the use of RRT was. The included studies used different definitions of baseline creatinine: some used admission sCr, and others used sCr obtained prior to admission. When creatinine obtained prior to admission was used, 28% to 51% of patients had missing values when reported. The handling of missing baseline values varied: some used admission creatinine, some used back calculating with the Modification of Diet in Renal Disease (MDRD) formula, and one study used multiple imputation. Seven studies used NGAL samples at or close to admission to evaluate AuROC for AKI, whereas two studies reported that AuROC values were retrospectively based on NGAL samples taken on a fixed time point prior to AKI (12 hours and 2 to 3 days, respectively).

According to our predefined risk-of-bias assessment, nine studies had low and two studies medium risk of bias (Table [2](#T2){ref-type="table"}). In all studies having use of RRT as an outcome measure, clinicians were blinded to NGAL concentrations, reducing the risk of NGAL values affecting the decision to use RRT.

###### 

Assessment of methodological quality and risk of bias in the included studies

  Study                            Prospective observational study design   Clearly described selection criteria   Validated diagnostic scale for AKI used   Clearly described NGAL measurements   Conflict of interests   Risk of bias
  -------------------------------- ---------------------------------------- -------------------------------------- ----------------------------------------- ------------------------------------- ----------------------- --------------
  de Geus *et al.*\[[@B21]\]       Yes                                      Yes                                    Yes                                       Yes                                   Yes                     Low
  Endre *et al.*\[[@B22]\]         Yes                                      Yes                                    Yes                                       Yes                                   Yes                     Low
  Doi *et al.*\[[@B24]\]           Yes                                      Yes                                    Yes                                       Yes                                   No                      Low
  Cruz *et al.*\[[@B25]\]          Yes                                      Yes                                    Yes                                       Yes                                   No                      Low
  Constantin *et al.*\[[@B26]\]    Yes                                      Yes                                    Yes                                       Yes                                   ?                       Low
  Mårtensson *et al.*\[[@B27]\]    No                                       Yes                                    Yes                                       Yes                                   ?                       Medium
  Metzger *et al.*\[[@B28]\]       No                                       Yes                                    Yes                                       Yes                                   Yes                     Medium
  Siew *et al.*\[[@B29]\]          Yes                                      Yes                                    Yes                                       Yes                                   No                      Low
  Makris *et al.*\[[@B30]\]        Yes                                      Yes                                    Yes                                       Yes                                   ?                       Low
  Kokkoris *et al*.^a^\[[@B31]\]   Yes                                      Yes                                    Yes                                       Yes                                   No                      Low
  Linko *et al*.^b^                Yes                                      Yes                                    N/A                                       Yes                                   No                      Low

^a^Study published as abstract only; author contacted to obtain extracted data; ^b^study unpublished. AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated lipocalin.

Value of NGAL to predict study outcomes
---------------------------------------

Table [3](#T3){ref-type="table"} shows the results of the included studies\' primary analyses of the value of NGAL to predict AKI, RRT, and mortality. The incidence of AKI across the studies ranged from 14% to 72% of patients included in the primary analyses. The follow-up time from the assessment of NGAL to AKI ranged from 12 hours to 1 week. The AuROC values for prediction of AKI ranged from 0.54 to 0.98 in all included studies and from 0.54 to 0.92 in the studies of general ICU patients. In five studies, AuROC for prediction of use of RRT was performed and these ranged from 0.73 to 0.89. The four studies reporting prediction of both RRT and AKI had AuROCs of 0.79 to 0.89 for use of RRT and 0.55 to 0.92 for AKI. In five studies, prediction of mortality was assessed and AuROCs ranged from 0.58 to 0.83. In four studies, author-defined cutoff values of NGAL for AKI were reported (Table [3](#T3){ref-type="table"}). In four studies, sensitivity analyses were conducted to exclude patients with pre-existing reduced kidney function (Table [4](#T4){ref-type="table"}). In the remaining studies in which sensitivity analyses were not performed, kidney-specific characteristics of patients included in the primary analyses were presented.

###### 

Neutrophil gelatinase-associated lipocalin and prediction of study outcome measures

  Study                                    AKI events, percentage (number)   12 hours          24 hours          AuROC 48 hours    72 hours   5 days            7 days            RRT events, percentage (number)   RRT AuROC         Mortality events, percentage (number)   Mortality AuROC   NGAL cutoff value for AKI   Sensitivity   Specificity   PPV    NPV
  ---------------------------------------- --------------------------------- ----------------- ----------------- ----------------- ---------- ----------------- ----------------- --------------------------------- ----------------- --------------------------------------- ----------------- --------------------------- ------------- ------------- ------ ------
  de Geus *et al.*\[[@B21]\] (plasma)      27% (171)                         \-                \-                \-                \-         \-                0.77 ± 0.05       4% (28)                           0.88 ± 0.06       Hospital 22% (137)                      0.63 ± 0.06       \-                          \-            \-            \-     \-
  de Geus \[[@B12]\]*et al*. (urine)       27% (171)                         \-                \-                \-                \-         \-                0.80 ± 0.04       4% (28)                           0.89 ± 0.04       Hospital 22% (137)                      0.64 ± 0.06       \-                          \-            \-            \-     \-
  Endre *et al*.^a^\[[@B22]\] (urine)      22% (82)                          \-                \-                0.55(0.48-0.67)   \-         \-                0.68(0.56-0.80)   4% (19)                           0.79(0.65-0.94)   7 days 10% (53)                         0.66(0.57-0.74)   \-                          \-            \-            \-     \-
  Doi *et al.*\[[@B24]\] (urine)           39% (131)                         \-                \-                \-                \-         \-                0.70(0.63-0.75)   \-                                \-                14 days 4% (14)                         0.83(0.69-0.91)   \-                          \-            \-            \-     \-
  Cruz *et al*.^b^\[[@B25]\] (plasma)      14% (43)                          \-                \-                0.78(0.65-0.90)   \-         0.67(0.55-0.79)   \-                5% (15)                           0.82(0.70-0.95)   in ICU 17% (52)                         0.67(0.58-0.77)   150 ng/mL 48 hours          0.73          0.81          0.24   0.97
                                                                                                                                                                                                                                                                                                5 days                      0.46          0.80          0.26   0.91
  Constantin *et al.*\[[@B26]\] (plasma)   59% (52)                          \-                \-                \-                \-         \-                0.92(0.85-0.97)   8% (7)                            0.79(0.69-0.87)   in ICU 19% (17)                         \-                155 ng/mL                   0.83          0.97          0.97   0.80
  Mårtensson *et al.*\[[@B27]\] (plasma)   72% (18)                          0.67(0.39-0.94)   \-                \-                \-         \-                \-                4% (1)                            \-                30 days 24% (6)                         \-                120 ng/mL                   0.83          0.50          \-     \-
  Mårtensson *et al.*\[[@B27]\] (urine)    72% (18)                          0.86(0.68-1.0)    \-                \-                \-         \-                \-                4% (1)                            \-                30 days 24% (6)                         \-                68 ng/mgCr                  0.71          1.0           \-     \-
  Metzger *et al.*\[[@B28]\] (urine)       45% (9)                           \-                \-                0.54^c^           \-         \-                \-                20% (4)                           \-                \-                                      \-                \-                          \-            \-            \-     \-
  Siew *et al.*\[[@B29]\] (urine)          19% (86)                          \-                0.71(0.63-0.78)   0.64(0.57-71)     \-         \-                \-                3% (17)                           \-                28 days 17% (83)                        \-                \-                          \-            \-            \-     \-
  Makris *et al.*\[[@B30]\] (urine)        35% (11)                          \-                \-                \-                \-         0.98(0.82-0.98)   \-                \-                                \-                in ICU 23% (7)                          \-                25 ng/mL                    0.91          0.95          \-     \-
  Kokkoris *et al.*\[[@B31]\] (plasma)     26% (24)                          \-                \-                \-                0.78       \-                \-                8% (7)                            \-                in ICU 33% (30)                         \-                110 ng/mL                   0.71          0.82          \-     \-
  Linko *et al*. ^d^(plasma)               \-                                \-                \-                \-                \-         \-                \-                13% (47)                          0.73(0.66-0.81)   90 days 30% (111)                       0.58(0.52-0.65)   \-                          \-            \-            \-     \-

Area under receiver operating characteristic curve (AuROC): (95% confidence interval) or ± 2 × standard error. ^a^Of 528 included patients, 147 had acute kidney injury (AKI) on entry and were not included in primary analysis of AKI but were included in analysis of renal replacement therapy (RRT) and mortality. Study reported AuROC at 48 hours with Acute Kidney Injury Network (AKIN) criteria, whereas AuROC at 7 days was with RIFLE criteria sustained for a minimum of 24 hours; ^b^of 301 included patients, 90 had AKI on entry and were not included in calculation of AuROC values; ^c^author reported AuROC based on sample 2 to 3 days prior to AKI. ^d^study unpublished. ADQI, Acute Dialysis Quality Initiative; GFR, glomerular filtration rate; ICU, intensive care unit; lcn2, lipocalin-2; MDRD, Modification of Diet in Renal Disease; NGAL, neutrophil gelatinase-associated lipocalin; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney disease; NPV, negative predictive value; PPV, positive predictive value; sCr, serum creatinine.

###### 

Sensitivity analyses for prediction of acute kidney injury excluding patients with author-defined reduced kidney function on entry

  Study                                    Patients excluded                                                                                   Number of patients included in analysis   AuROC sensitivity analysis             AuROC primary analysis
  ---------------------------------------- --------------------------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------- --------------------------------------
  de Geus *et al.*\[[@B21]\] (plasma)      eGFR \<60 mL/minute/1.73 m^2^at admission                                                           498, of whom 7% (37) developed AKI        AKI within 7 days 0.75 ± 0.10          AKI within 7 days 0.77 ± 0.05
  de Geus *et al.*\[[@B21]\] (urine)       eGFR \<60 mL/minute/1.73 m^2^at admission                                                           498, of whom 7% (37) developed AKI        AKI within 7 days 0.79 ± 0.10          AKI within 7 days 0.80 ± 0.04
  Doi *et al.*\[[@B24]\] (urine)           AKI at admission                                                                                    274, of whom 24% (66) developed AKI       AKI within 7 days 0.60 (0.52-0.67)     AKI within 7 days 0.70 (0.63-0.75)
  Constantin *et al.*\[[@B26]\] (plasma)   AKI at admission                                                                                    56, of whom 36% (20) developed AKI        AKI within 7 days 0.96 (0.86-0.99)     AKI within 7 days 0.92 (0.85-0.97)
  Siew *et al.*\[[@B29]\] (urine)          eGFR \<75 mL/minute/1.73 m^2^at admission                                                           275, of whom 7% (18) developed AKI        AKI within 24 hours 0.77 (0.64-0.90)   AKI within 24 hours 0.71 (0.63-0.78)
  Cruz *et al.*\[[@B25]\] (plasma)         Only patients without AKI at enrollment were included in primary analyses.                                                                                                           
  Makris *et al.*\[[@B30]\] (urine)        Only patients with sCr \<1.5 mg/dL (133 μmol/L) on entry were included in primary analysis.                                                                                          
  Endre *et al.*\[[@B22]\] (urine)         Only patients without AKI on entry were included in primary analysis.                                                                                                                
  Metzger *et al.*\[[@B28]\] (urine)       Only patients without AKI within 48 hours of admission were included in primary analysis.                                                                                            
  Mårtensson *et al.*\[[@B27]\] (plasma)   Only patients with eGFR \>60 mL/minute/1.73 m^2^on entry were included in primary analysis.                                                                                          
  Mårtensson *et al.*\[[@B27]\] (urine)    Only patients with eGFR \>60 mL/minute/1.73 m^2^on entry were included in primary analysis.                                                                                          
  Kokkoris *et al.*\[[@B31]\] (plasma)     Only patients with known baseline sCr \<1.6 mg/dL (141 μmol/L) were included in primary analysis.                                                                                    

Area under receiver operating characteristic curve (AuROC) presented as ± 2 × standard error or (95% confidence interval). AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; sCR, serum creatinine.

Two studies conducted analyses stratifying for AKI severity. The results are presented in Table [5](#T5){ref-type="table"}, showing increase in AuROC values with increasing degree of AKI. Our plans of conducting a meta-analysis and a subgroup analysis of patients with sepsis were aborted because of heterogeneity and lack of data, respectively; see the Discussion for further argumentation.

###### 

Values of area under receiver operating characteristic curve stratified for severity of acute kidney injury

  Study                                 RIFLE R or above   RIFLE I or above   RIFLE F       AKIN I             AKIN II, III combined
  ------------------------------------- ------------------ ------------------ ------------- ------------------ -----------------------
  de Geus *et al.*\[[@B21]\] (plasma)   0.77 ± 0.05        0.80 ± 0.06        0.86 ± 0.06   \-                 \-
  de Geus *et al.*\[[@B21]\] (urine)    0.80 ± 0.04        0.85 ± 0.04        0.88 ± 0.04   \-                 \-
  Siew *et al.*\[[@B29]\] (urine)       \-                 \-                 \-            0.62 (0.54-0.70)   0.71 (0.59-0.83)

Area under receiver operating characteristic curve presented as ± 2 × standard errors or (95% confidence intervals). AKIN, Acute Kidney Injury Network; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney disease.

Discussion
==========

The aim of this review was to systematically evaluate articles investigating the value of plasma or urinary NGAL (or both) to predict AKI in adult ICU patients. The results of the included studies varied greatly, as did those of studies in general ICU patients only. Put another way, the results ranged from a predictive value equivalent to flipping a coin to NGAL being an excellent early marker of AKI. A reason for these results may be the marked differences in study design. The observation period for AKI varied greatly between studies, but there was no clear association between length of observation period and AuROC as studies with observation periods of 5 days or more appeared to have higher AuROC values. However, the two studies reporting AuROC values for more than one observational period using same AKI definition showed a decline in AuROC with longer observation period. Also, kidney-specific characteristics of patients included in the calculation of AuROC varied, making direct comparison between studies less reliable; this probably contributed to the marked range in AKI incidence even among studies performed in general ICU populations.

When RIFLE or AKIN criteria are used to define AKI, a baseline creatinine value for each included patient is required. The included studies used different definitions of baseline creatinine (see Supplemental Digital Content), and this may have caused one patient to be classified as having AKI in one study but not in another, even though the studies appeared to use the same criteria for AKI. Some studies excluded patients with reduced kidney function at inclusion, whereas others conducted a sensitivity analysis based on author-defined kidney impairment. We believe the latter approach to be more appropriate because it provides more information to clinicians and researchers. Moreover, the varying methods in the individual studies make it difficult to compare the results.

For the studies reporting the secondary outcomes, use of RRT and mortality NGAL performed more homogenously than for AKI. Studies reporting AuROC for both use of RRT and AKI showed that NGAL performed more homogenously well in predicting use of RRT than in predicting AKI. This finding, combined with the finding that NGAL performed better with increasing severity of AKI, indicates that NGAL has greater potential as an early marker of severe AKI in the ICU. A possible explanation is that ICU populations have higher levels of comorbidity and thereby other sources of NGAL, but further studies are needed to confirm this hypothesis. For the five studies reporting the value of NGAL to predict mortality, NGAL performed homogenously poorly with the exception of one study with low mortality rate.

Two studies evaluated both plasma and urinary NGAL. The largest study of this review with 632 participants found no significant difference between AuROC for plasma and urinary NGAL; this is interesting given the presumed differences in metabolism of plasma and urinary NGAL.

As noted, some studies used urinary NGAL-creatinine ratios as opposed to absolute NGAL concentrations. A recent study showed significant increase in intra-individual variations in urinary NGAL when using absolute concentrations compared with concentrations normalized to creatinine \[[@B17]\]. Using NGAL concentrations normalized to creatinine, however, has also been criticized, especially during non-steady state as in AKI, in which urinary creatinine excretion rate changes over time and there is active tubular secretion of creatinine \[[@B18]\]. The recommendation given in the latter article was to use timed collections providing biomarker excretion rates. A comparison of the three methods of measuring NGAL was conducted by Endre and colleagues \[[@B19]\], who showed comparable AuROC values for NGAL to predict outcomes, though favoring normalizing to urinary creatinine.

We aimed to conduct a meta-analysis, but given the variations in study design, we do not believe that meta-analyses would contribute useful data on the value of NGAL to predict AKI. As only one study was conducted exclusively in patients with sepsis and none of the other studies reported AuROC for this subgroup, the planned subgroup analysis was also aborted.

There are general limitations and challenges when conducting studies evaluating the value of NGAL to predict AKI. Firstly, the use of creatinine-based AKI definition as reference standard is challenging. Creatinine is not an ideal marker of AKI and this poses a challenge when conducting studies evaluating potential early markers of AKI. A recent meta-analysis of cardiac surgical and ICU patients proposed that an NGAL increase in patients not fulfilling conventional AKI criteria may be a sign of subclinical AKI with significantly increased risk of need of RRT and not a false-positive test result as often reported \[[@B20]\]. Whether or not this theory applies when exclusively examining ICU patients with presumably more abundant sources of confounding NGAL is not known, but further studies are called for. Secondly, the handling of missing baseline creatinine values may confound results. The Acute Dialysis Quality Initiative (ADQI) recommends back-calculating from the MDRD formula from an estimated GFR of 75 mL/minute per 1.73 m^2^\[[@B14]\], but controversy exists, resulting in great variations in the handling of missing baseline values. Thirdly, the observation period from NGAL sampling to AKI by conventional criteria poses a challenge. The longer the observation period, the higher the risk of including renal insults acquired after NGAL sampling. Conversely, if the time period is short, there is a risk of excluding late AKI.

More studies are needed to further clarify the role of NGAL as an early marker of AKI in intensive care patients. Some form of consensus of study design is paramount in order to make comparison of results more meaningful. Studies on selected patient groups in the ICU would be desirable as general ICU patients constitute a heterogenic population. We recommend calculating AuROC for AKI based on patients not fulfilling AKI criteria on entry and applying ADQI recommendations when missing baseline creatinine value obtained prior to admission. The proportion of patients with missing baseline creatinine should be stated, and a sensitivity analysis excluding these patients would be desirable. Given the characteristics of NGAL, an AKI observation period of approximately 3 to 5 days seems to be appropriate. The optimal quantification method of urinary NGAL has not yet been established, and we recommend reporting both absolute concentration and concentration normalized to creatinine and, if possible, the NGAL excretion rate.

Conclusions
===========

This systematic review has shown that studies evaluating plasma and urinary NGAL as early markers of AKI in ICU patients showed great heterogeneity in design and results. The results varied from NGAL being virtually useless to NGAL being an excellent early marker of AKI. The results for the secondary outcome measures use of RRT and mortality were more homogenous, with NGAL being a reasonable predictor of use of RRT. In contrast, NGAL appeared to be a poor predictor of mortality.

Key messages
============

• The results of the value of plasma and urinary NGAL in predicting AKI in intensive care patients varied, and so NGAL cannot at present be recommended as a marker of AKI in the ICU.

• Differences in study design, including observation period for AKI, NGAL quantification method, and kidney-specific patient characteristics, made comparison across studies less reliable and led to the aborting of a planned meta-analysis.

• Studies investigating the value of NGAL in predicting the use of renal replacement therapy showed homogenously reasonable predictive value of NGAL.
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